Fig. 6: MECOM controls KRAS transcription by binding it’s promoter and is responsive to inhibitory action of JIB-04. | Cell Death Discovery

Fig. 6: MECOM controls KRAS transcription by binding it’s promoter and is responsive to inhibitory action of JIB-04.

From: Epigenetic targeting of MECOM/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer

Fig. 6

A Significant positive correlation of MECOM with KRAS expression in ovarian cancer samples (n = 303). B RT-qPCR of KRAS in MECOM deficient SKOV3 cells. C RT-qPCR of KRAS in E-JIB-04 and Z-JIB-04 treated SKOV3 cells. D Schematic of ChIP-qPCR primers on KRAS promoter. E Chromatin immunoprecipitation-qPCR was performed using antibodies targeting MECOM and H3K4me3, and qPCR was performed to check for its binding on KRAS promoter region in presence or absence of E-JIB-04 treatment. ChIP-qPCR using primer 2 showed decreased occupancy of MECOM on KRAS promoter in E-JIB-04 treated cells compared to vehicle-treated cells.

Back to article page